ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2009
Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 37 citations in OpenAlex.
- Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2012Trial
- A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis.Journal of personalized medicine · 2022Article
- gMS-Classifier1 does not predict disability progression in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Article
- Evaluation of anti α-d-GlcRSC advances · 2018Article
- Manipulation of the glycan-specific natural antibody repertoire for immunotherapy.Immunological reviews · 2016Review
- Serum biomarker gMS-Classifier2: predicting conversion to clinically definite multiple sclerosis.PloS one · 2013Article
- Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.Metabolites · 2012Article
- Need for a paradigm shift in therapeutic approaches to CNS injury.Expert review of neurotherapeutics · 2012Review
- Is multiple sclerosis an autoimmune disease?Autoimmune diseases · 2012Article
- Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis.Neurology research international · 2011Article
- Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis.PloS one · 2011Article
- Construction and use of glycan microarrays.Current protocols in chemical biology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is no specific serum-based biomarker for the diagnosis or prognosis of relapsing-remitting multiple sclerosis (RRMS).
objectiveWe investigated whether levels of IgM antibodies to Glc(alpha1,4)Glc(alpha) (GAGA4) or to a panel of four glucose-based glycans could differentiate MS from other neurological diseases (OND) or predict risk of early relapse following first presentation (FP) of RRMS.
methodsRetrospective analysis of 440 sera samples of three cohorts: A) FP-RRMS (n = 44), OND (n = 44); B) FP-RRMS (n = 167), OND (n = 85); and C) FP (n = 100). Anti-GAGA4 IgM levels were measured by enzyme immunoassay in cohort-A and cohort-B. Cohort-C IgM antibodies to glucose-based glycan panel were measured by immunofluorescence.
resultsFP-RRMS had higher levels of anti-GAGA4 IgM than OND patients (cohort-A, P = 0.01; cohort-B, P = 0.0001). Sensitivity and specificity were 27% and 97% for cohort-A; and 26% and 90% for cohort-B, respectively. In cohort-C, 58 patients experienced early relapse (<24 months), 31 had late relapse (> or =24 months), and 11 did not experience second attack during follow-up. Kaplan-Meier curves demonstrated decrease in time to next relapse for patients positive for the antibody panel (P = 0.02, log rank).
conclusionsSerum anti-GAGA4 IgM discerns FP-RRMS patients from OND patients. Higher levels of serum anti-alpha-glucose IgM in FP patients predict imminent early relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.